NASDAQ:IDXX - Idexx Laboratories Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$204.16 +4.17 (+2.09 %)
(As of 05/24/2018 07:05 AM ET)
Previous Close$199.99
Today's Range$199.44 - $204.56
52-Week Range$146.09 - $217.89
Volume503,156 shs
Average Volume539,090 shs
Market Capitalization$17.37 billion
P/E Ratio62.24
Dividend YieldN/A
Beta0.6

About Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories logoIDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Debt-to-Equity Ratio-12.43
Current Ratio0.96
Quick Ratio0.72

Price-To-Earnings

Trailing P/E Ratio62.24
Forward P/E Ratio49.08
P/E Growth2.38

Sales & Book Value

Annual Sales$1.97 billion
Price / Sales9.01
Cash Flow$4.4162 per share
Price / Cash46.23
Book Value($0.56) per share
Price / Book-364.57

Profitability

EPS (Most Recent Fiscal Year)$3.28
Net Income$263.14 million
Net Margins13.87%
Return on Equity-530.24%
Return on Assets19.39%

Miscellaneous

Employees7,600
Outstanding Shares86,860,000

Idexx Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is Idexx Laboratories' stock symbol?

Idexx Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will Idexx Laboratories' stock buyback program work?

Idexx Laboratories announced that its Board of Directors has authorized a stock repurchase plan on Sunday, June 4th 2017, which authorizes the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

How were Idexx Laboratories' earnings last quarter?

Idexx Laboratories (NASDAQ:IDXX) released its quarterly earnings results on Friday, May, 4th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.92 by $0.09. The firm earned $537.60 million during the quarter, compared to analyst estimates of $525.14 million. Idexx Laboratories had a negative return on equity of 530.24% and a net margin of 13.87%. The firm's revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.77 EPS. View Idexx Laboratories' Earnings History.

When is Idexx Laboratories' next earnings date?

Idexx Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Idexx Laboratories.

What guidance has Idexx Laboratories issued on next quarter's earnings?

Idexx Laboratories issued an update on its FY18 earnings guidance on Friday, May, 4th. The company provided earnings per share (EPS) guidance of $4.06-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.11. The company issued revenue guidance of +12-14% to ~$2.205-2.245 billion, compared to the consensus revenue estimate of $2.22 billion.

What price target have analysts set for IDXX?

6 brokerages have issued twelve-month price objectives for Idexx Laboratories' stock. Their predictions range from $118.00 to $225.00. On average, they anticipate Idexx Laboratories' stock price to reach $198.1667 in the next twelve months. View Analyst Ratings for Idexx Laboratories.

Who are some of Idexx Laboratories' key competitors?

Who are Idexx Laboratories' key executives?

Idexx Laboratories' management team includes the folowing people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 62)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 56)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Sec. (Age 59)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 54)
  • Mr. Jay Mazelsky, Exec. VP (Age 57)

Has Idexx Laboratories been receiving favorable news coverage?

Media coverage about IDXX stock has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Idexx Laboratories earned a news impact score of 0.17 on Accern's scale. They also gave news stories about the company an impact score of 48.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Idexx Laboratories' major shareholders?

Idexx Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.61%), Bamco Inc. NY (5.15%), Blair William & Co. IL (1.87%), Neuberger Berman Group LLC (1.86%), Northern Trust Corp (1.16%) and Old Mutual Global Investors UK Ltd. (1.08%). Company insiders that own Idexx Laboratories stock include Barry C Johnson, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for Idexx Laboratories.

Which major investors are selling Idexx Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bamco Inc. NY, Blair William & Co. IL, Millennium Management LLC, Federated Investors Inc. PA, Natixis, American Century Companies Inc. and Old Mutual Global Investors UK Ltd.. Company insiders that have sold Idexx Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for Idexx Laboratories.

Which major investors are buying Idexx Laboratories stock?

IDXX stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, AGF Investments Inc., Prudential Financial Inc., OppenheimerFunds Inc., Westfield Capital Management Co. LP, Wells Fargo & Company MN, Select Equity Group L.P. and Chicago Capital LLC. Company insiders that have bought Idexx Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for Idexx Laboratories.

How do I buy shares of Idexx Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Idexx Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $204.16.

How big of a company is Idexx Laboratories?

Idexx Laboratories has a market capitalization of $17.37 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. Idexx Laboratories employs 7,600 workers across the globe.

How can I contact Idexx Laboratories?

Idexx Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


MarketBeat Community Rating for Idexx Laboratories (IDXX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  511
MarketBeat's community ratings are surveys of what our community members think about Idexx Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Idexx Laboratories (NASDAQ:IDXX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Idexx Laboratories in the last 12 months. Their average twelve-month price target is $198.1667, suggesting that the stock has a possible downside of 2.94%. The high price target for IDXX is $225.00 and the low price target for IDXX is $118.00. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.672.672.672.33
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $198.1667$190.6667$190.6667$171.60
Price Target Upside: 2.94% downside0.96% downside0.96% downside4.36% upside

Idexx Laboratories (NASDAQ:IDXX) Consensus Price Target History

Price Target History for Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2018Canaccord GenuityReiterated RatingBuy ➝ Positive$215.00HighView Rating Details
5/7/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$215.00 ➝ $225.00HighView Rating Details
2/2/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$200.00 ➝ $220.00HighView Rating Details
2/1/2018Piper Jaffray CompaniesBoost Price TargetOverweight$211.00HighView Rating Details
12/8/2017AegisReiterated RatingSellLowView Rating Details
7/28/2017CL KingUpgradeNeutral ➝ Buy$200.00MediumView Rating Details
2/3/2017Feltl & Co.DowngradeHold ➝ SellN/AView Rating Details
8/3/2016Northcoast ResearchUpgradeSell ➝ NeutralN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Idexx Laboratories (NASDAQ:IDXX) Earnings History and Estimates Chart

Earnings by Quarter for Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) Earnings Estimates

2018 EPS Consensus Estimate: $3.95
2019 EPS Consensus Estimate: $4.74
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.90$0.91$0.91
Q2 20182$1.18$1.20$1.19
Q3 20182$0.97$0.98$0.98
Q4 20182$0.77$0.99$0.88
Q1 20192$1.01$1.05$1.03
Q2 20192$1.38$1.40$1.39
Q3 20192$1.17$1.19$1.18
Q4 20192$1.13$1.15$1.14

Idexx Laboratories (NASDAQ IDXX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018N/AView Earnings Details
5/4/2018Q1 2018$0.92$1.01$525.14 million$537.60 millionViewN/AView Earnings Details
2/1/2018Q4 2017$0.73$0.77$490.51 million$506.00 millionViewN/AView Earnings Details
10/31/2017Q3 2017$0.74$0.79$492.94 million$492.00 millionViewN/AView Earnings Details
8/1/2017Q2 2017$0.85$0.95$502.44 million$508.90 millionViewListenView Earnings Details
4/28/2017Q1 17$0.61$0.77$455.10 million$462.00 millionViewN/AView Earnings Details
2/2/2017Q416$0.51$0.58$436.07 million$443.00 millionViewListenView Earnings Details
11/1/2016Q316$0.59$0.62$448.60 million$448.30 millionViewListenView Earnings Details
8/2/2016Q216$0.62$0.74$444.83 million$467.00 millionViewListenView Earnings Details
4/29/2016Q116$0.47$0.51$403.48 million$417.55 millionViewListenView Earnings Details
1/29/2016Q415$0.44$0.48$397.39 million$400.00 millionViewListenView Earnings Details
10/28/2015Q315$0.53$0.54$409.33 million$406.00 millionViewListenView Earnings Details
7/30/2015Q215$0.57$0.60$412.57 million$413.30 millionViewListenView Earnings Details
4/28/2015Q115$0.98$0.98$394.38 million$382.00 millionViewN/AView Earnings Details
1/30/2015Q414$0.80$0.95$373.20 million$352.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.90$1.05$371.80 million$384.00 millionViewListenView Earnings Details
7/25/2014Q214$1.06$1.10$385.20 million$390.00 millionViewN/AView Earnings Details
4/25/2014Q114$0.87$0.89$361.58 million$360.20 millionViewListenView Earnings Details
2/4/2014Q413$0.81$0.82$347.08 million$354.10 millionViewN/AView Earnings Details
10/22/2013Q313$0.83$0.86$339.70 million$338.30 millionViewN/AView Earnings Details
7/23/2013Q2 2013$0.97$0.99$356.80 million$352.60 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.83$0.81$341.06 million$332.10 millionViewN/AView Earnings Details
1/29/2013Q4 2012$0.71$0.78$325.10 million$319.50 millionViewN/AView Earnings Details
10/19/2012$0.73$0.76ViewN/AView Earnings Details
7/20/2012$0.90$0.91ViewN/AView Earnings Details
4/20/2012$0.71$0.72ViewN/AView Earnings Details
1/27/2012$0.63$0.67ViewN/AView Earnings Details
10/21/2011$0.65$0.66ViewN/AView Earnings Details
7/22/2011$0.72$0.83ViewN/AView Earnings Details
4/21/2011$0.59$0.62ViewN/AView Earnings Details
1/28/2011$0.55$0.62ViewN/AView Earnings Details
10/22/2010Q3 2010$0.28$0.29ViewN/AView Earnings Details
7/23/2010Q2 2010$0.31$0.31ViewN/AView Earnings Details
4/23/2010Q1 2010$0.25$0.28ViewN/AView Earnings Details
1/29/2010Q4 2009$0.23$0.26ViewN/AView Earnings Details
10/23/2009Q3 2009$0.23$0.26ViewN/AView Earnings Details
7/24/2009Q2 2009$0.27$0.28ViewN/AView Earnings Details
4/24/2009Q1 2009$0.19$0.22ViewN/AView Earnings Details
1/30/2009Q4 2008$0.21$0.22ViewN/AView Earnings Details
10/24/2008Q3 2008$0.20$0.21ViewN/AView Earnings Details
7/25/2008Q2 2008$0.28$0.32ViewN/AView Earnings Details
4/25/2008Q1 2008$0.20$0.21ViewN/AView Earnings Details
1/25/2008Q4 2007$0.20$0.20ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Idexx Laboratories (NASDAQ:IDXX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Idexx Laboratories (NASDAQ IDXX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.56%
Institutional Ownership Percentage: 86.14%
Insider Trading History for Idexx Laboratories (NASDAQ:IDXX)
Institutional Ownership by Quarter for Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ IDXX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2018William T EndDirectorSell9,470$208.36$1,973,169.2031,786View SEC Filing  
2/28/2018Daniel M JuniusDirectorSell2,974$190.06$565,238.445,602View SEC Filing  
2/22/2018William T EndDirectorSell4,000$184.48$737,920.0041,256View SEC Filing  
2/14/2018Lawrence D KingsleyDirectorBuy1,000$178.05$178,050.004,558View SEC Filing  
2/8/2018Jonathan W AyersChairmanSell22,000$177.52$3,905,440.001,077,112View SEC Filing  
2/7/2018Bruce L ClaflinDirectorBuy1,000$179.58$179,580.001,000View SEC Filing  
2/6/2018Jonathan W AyersChairmanSell36,000$179.28$6,454,080.001,077,112View SEC Filing  
2/5/2018Brian P MckeonVPSell6,602$181.36$1,197,338.7247,040View SEC Filing  
1/11/2018Jonathan W AyersCEOSell2,160$167.03$360,784.801,077,112View SEC Filing  
1/9/2018Jonathan W AyersCEOSell18,000$165.15$2,972,700.001,077,112View SEC Filing  
11/30/2017Giovani TwiggeInsiderSell2,000$156.07$312,140.00View SEC Filing  
11/16/2017Jonathan W AyersCEOSell18,000$153.61$2,764,980.001,064,573View SEC Filing  
11/14/2017Jonathan W AyersCEOSell18,000$148.35$2,670,300.001,064,573View SEC Filing  
11/7/2017Jonathan W AyersChairmanSell54,000$151.32$8,171,280.001,064,573View SEC Filing  
11/3/2017Jonathan W AyersCEOSell18,000$153.75$2,767,500.001,064,573View SEC Filing  
8/28/2017Jonathan W AyersChairmanSell13,000$150.79$1,960,270.001,044,034View SEC Filing  
8/23/2017Rebecca M HendersonDirectorSell5,156$153.29$790,363.2417,274View SEC Filing  
8/22/2017Rebecca M HendersonDirectorSell2,578$152.86$394,073.0817,274View SEC Filing  
8/16/2017Jonathan W AyersChairmanSell58,000$155.00$8,990,000.001,043,034View SEC Filing  
8/15/2017Jonathan W AyersCEOSell20,000$154.62$3,092,400.001,043,034View SEC Filing  
8/14/2017Jonathan W AyersCEOSell18,000$154.91$2,788,380.001,043,034View SEC Filing  
8/9/2017Jonathan W AyersChairmanSell17,000$154.54$2,627,180.001,039,034View SEC Filing  
8/8/2017Jonathan W. AyersChairmanSell18,000$155.22$2,793,960.00View SEC Filing  
8/3/2017Lawrence D KingsleyDirectorBuy2,000$151.76$303,520.003,344View SEC Filing  
5/31/2017Giovani TwiggeInsiderSell2,572$166.90$429,266.80View SEC Filing  
5/30/2017Jonathan W AyersChairmanSell13,000$167.82$2,181,660.001,032,994View SEC Filing  
5/22/2017William T EndDirectorSell5,000$162.55$812,750.0045,256View SEC Filing  
5/10/2017Jonathan W AyersChairmanSell27,000$162.69$4,392,630.001,024,994View SEC Filing  
5/5/2017Jonathan W. AyersChairmanSell26,000$160.61$4,175,860.00View SEC Filing  
5/4/2017Rebecca M HendersonDirectorSell1,700$159.95$271,915.0021,552View SEC Filing  
3/1/2017Lawrence D KingsleyDirectorBuy1,000$146.48$146,480.001,135View SEC Filing  
2/22/2017Jonathan W AyersChairmanSell35,000$142.58$4,990,300.00995,947View SEC Filing  
2/8/2017Brian P MckeonVPSell9,924$141.64$1,405,635.3645,235View SEC Filing  
2/8/2017Daniel M JuniusDirectorSell3,000$141.75$425,250.005,495View SEC Filing  
2/8/2017Jonathan W. AyersChairmanSell36,250$141.63$5,134,087.50View SEC Filing  
11/29/2016Jonathan W AyersChairmanSell27,424$119.77$3,284,572.481,001,043View SEC Filing  
11/28/2016Jonathan W AyersCEOSell13,188$119.57$1,576,889.161,001,043View SEC Filing  
11/23/2016Thomas CraigDirectorSell8,500$120.06$1,020,510.0032,783View SEC Filing  
11/9/2016Jonathan W. AyersChairmanSell40,000$107.85$4,314,000.00View SEC Filing  
11/8/2016William T EndDirectorSell5,000$109.87$549,350.0048,654View SEC Filing  
8/25/2016Rebecca M HendersonDirectorSell9,924$110.43$1,095,907.3216,678View SEC Filing  
8/15/2016Barry C JohnsonDirectorSell9,924$111.37$1,105,235.8813,484View SEC Filing  
8/8/2016Michael J. Phd WilliamsInsiderSell49,560$108.94$5,399,066.40View SEC Filing  
8/5/2016William T EndDirectorSell5,000$108.50$542,500.0053,564View SEC Filing  
8/4/2016Jonathan W. AyersChairmanSell60,000$107.69$6,461,400.00View SEC Filing  
5/5/2016William T EndDirectorSell4,924$85.87$422,823.8863,578View SEC Filing  
2/24/2016Michael J Phd WilliamsEVPSell2,000$71.93$143,860.0040,011View SEC Filing  
2/9/2016Thomas CraigDirectorSell2,054$69.52$142,794.0822,298View SEC Filing  
2/8/2016Brian P. MckeonCFOSell9,054$69.65$630,611.1032,461View SEC Filing  
11/30/2015Thomas CraigDirectorSell7,000$70.28$491,960.0022,048View SEC Filing  
11/12/2015Rebecca M. HendersonDirectorSell2,300$68.39$157,297.0021,450View SEC Filing  
8/31/2015Thomas CraigDirectorSell800$71.77$57,416.0021,793View SEC Filing  
8/18/2015Michael J. Phd WilliamsEVPSell6,586$78.34$515,947.2439,654View SEC Filing  
8/18/2015Thomas CraigDirectorSell2,900$79.41$230,289.0022,593View SEC Filing  
8/17/2015Jonathan W AyersCEOSell14,799$78.45$1,160,981.55View SEC Filing  
5/18/2015William T EndDirectorSell3,527$134.51$474,416.77View SEC Filing  
3/10/2015William T EndDirectorSell3,500$150.89$528,115.00View SEC Filing  
3/4/2015Johnny D PowersEVPSell6,168$158.49$977,566.32View SEC Filing  
2/17/2015Brian P MckeonCFOSell5,000$156.99$784,950.00View SEC Filing  
2/12/2015Jonathan W AyersCEOSell58,245$155.45$9,054,185.25View SEC Filing  
2/5/2015Rebecca M HendersonDirectorSell2,934$156.27$458,496.18View SEC Filing  
2/4/2015Thomas CraigDirectorSell2,200$157.02$345,444.00View SEC Filing  
1/14/2015Jonathan W AyersCEOSell28,512$157.68$4,495,772.16View SEC Filing  
12/3/2014Jonathan W AyersCEOSell29,000$148.49$4,306,210.00View SEC Filing  
11/13/2014Thomas CraigDirectorSell5,000$152.45$762,250.00View SEC Filing  
11/5/2014Jonathan W AyersCEOSell29,000$143.45$4,160,050.00View SEC Filing  
11/4/2014Johnny D PowersEVPSell1,292$142.70$184,368.40View SEC Filing  
8/13/2014M Anne SzostakDirectorBuy2,000$127.03$254,060.00View SEC Filing  
2/20/2014M Anne SzostakDirectorBuy2,000$126.71$253,420.005,000View SEC Filing  
2/19/2014Thomas CraigDirectorSell4,800$125.42$602,016.0011,976View SEC Filing  
2/3/2014Jonathan AyersCEOSell81,294$112.46$9,142,323.24389,665View SEC Filing  
11/26/2013Jonathan AyersCEOSell78,178$105.29$8,231,361.62377,211View SEC Filing  
11/22/2013Sophie VandebroekDirectorBuy1,000$107.84$107,840.001,000View SEC Filing  
11/13/2013Jonathan AyersCEOSell78,178$106.36$8,315,012.08365,389View SEC Filing  
11/4/2013M Anne SzostakDirectorBuy1,000$108.24$108,240.003,000View SEC Filing  
11/4/2013Michael Phd WilliamsEVPSell6,020$108.19$651,303.8011,566View SEC Filing  
10/31/2013William T EndDirectorSell2,500$108.32$270,800.00View SEC Filing  
10/25/2013Jonathan W AyersCEOSell78,178$104.36$8,158,656.08View SEC Filing  
9/13/2013Johnny PowersEVPSell13,128$96.59$1,268,033.528,989View SEC Filing  
9/5/2013Michael J Phd WilliamsEVPSell5,162$95.58$493,383.96View SEC Filing  
5/9/2013Ali NaquiVPSell12,961$87.00$1,127,607.00View SEC Filing  
2/4/2013Merilee RainesCFOSell175,929$94.25$16,581,308.25View SEC Filing  
11/13/2012Jonathan W AyersCEOSell15,000$89.92$1,348,800.00View SEC Filing  
9/5/2012Johnny D PowersEVPSell4,000$97.12$388,480.00View SEC Filing  
8/8/2012Merilee RainesCFOSell7,726$88.84$686,377.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Idexx Laboratories (NASDAQ IDXX) News Headlines

Source:
DateHeadline
Idexx Laboratories (IDXX) Receives Average Rating of "Buy" from AnalystsIdexx Laboratories (IDXX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 21 at 1:47 PM
Zacks: Brokerages Expect Idexx Laboratories (IDXX) Will Post Quarterly Sales of $574.95 MillionZacks: Brokerages Expect Idexx Laboratories (IDXX) Will Post Quarterly Sales of $574.95 Million
www.americanbankingnews.com - May 20 at 2:28 AM
IDEXX: This Medical Equipment Stock Is Overvalued And Could Go Down As Much As 20%IDEXX: This Medical Equipment Stock Is Overvalued And Could Go Down As Much As 20%
seekingalpha.com - May 19 at 8:03 AM
Zacks: Analysts Anticipate Idexx Laboratories (IDXX) Will Post Earnings of $1.18 Per ShareZacks: Analysts Anticipate Idexx Laboratories (IDXX) Will Post Earnings of $1.18 Per Share
www.americanbankingnews.com - May 18 at 7:35 PM
Idexx Laboratories (IDXX) Stock Rating Lowered by Zacks Investment ResearchIdexx Laboratories (IDXX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 18 at 4:45 PM
After the Bell: Dow Gains 63 Because Higher Bond Yields Dont Matter After AllAfter the Bell: Dow Gains 63 Because Higher Bond Yields Don't Matter After All
finance.yahoo.com - May 17 at 8:08 AM
BRIEF-IDEXX Laboratories says Reduced Board Size To EightBRIEF-IDEXX Laboratories says Reduced Board Size To Eight
www.reuters.com - May 16 at 8:05 AM
Critical Review: Idexx Laboratories (IDXX) & Trinity Biotech (TRIB)Critical Review: Idexx Laboratories (IDXX) & Trinity Biotech (TRIB)
www.americanbankingnews.com - May 12 at 11:33 AM
Idexx Laboratories (IDXX) Director Sells $1,973,169.20 in StockIdexx Laboratories (IDXX) Director Sells $1,973,169.20 in Stock
www.americanbankingnews.com - May 11 at 7:25 PM
IDEXX Laboratories Barks Out Another Successful QuarterIDEXX Laboratories Barks Out Another Successful Quarter
finance.yahoo.com - May 11 at 6:15 PM
Idexx Laboratories (IDXX) Rating Lowered to Buy at BidaskClubIdexx Laboratories (IDXX) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - May 10 at 12:37 AM
UPDATE: IDEXX Laboratories (IDXX) PT Raised to $225 at StifelUPDATE: IDEXX Laboratories (IDXX) PT Raised to $225 at Stifel
www.streetinsider.com - May 8 at 8:05 AM
IDEXX (IDXX) Hits a 52-Week High, Can the Run Continue?IDEXX (IDXX) Hits a 52-Week High, Can the Run Continue?
www.nasdaq.com - May 7 at 5:49 PM
Idexx Laboratories (IDXX) Price Target Increased to $225.00 by Analysts at Stifel NicolausIdexx Laboratories (IDXX) Price Target Increased to $225.00 by Analysts at Stifel Nicolaus
www.americanbankingnews.com - May 7 at 2:58 PM
Idexx Laboratories (IDXX) "Positive" Rating Reaffirmed at Canaccord GenuityIdexx Laboratories' (IDXX) "Positive" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - May 7 at 2:57 PM
Idexx Laboratories (IDXX) Q1 2018 Earnings Conference Call TranscriptIdexx Laboratories (IDXX) Q1 2018 Earnings Conference Call Transcript
www.fool.com - May 7 at 2:31 PM
BRIEF-Idexx Laboratories Reports Q1 Earnings Per Share $1.01BRIEF-Idexx Laboratories Reports Q1 Earnings Per Share $1.01
www.reuters.com - May 5 at 5:58 PM
Edited Transcript of IDXX earnings conference call or presentation 4-May-18 12:30pm GMTEdited Transcript of IDXX earnings conference call or presentation 4-May-18 12:30pm GMT
finance.yahoo.com - May 5 at 5:58 PM
Idexx Laboratories (IDXX) Posts  Earnings Results, Beats Estimates By $0.09 EPSIdexx Laboratories (IDXX) Posts Earnings Results, Beats Estimates By $0.09 EPS
www.americanbankingnews.com - May 4 at 8:33 PM
Idexx Laboratories (IDXX) Releases FY18 Earnings GuidanceIdexx Laboratories (IDXX) Releases FY18 Earnings Guidance
www.americanbankingnews.com - May 4 at 10:14 AM
IDEXX Laboratories Inc Q1 Profit ClimbsIDEXX Laboratories Inc Q1 Profit Climbs
www.nasdaq.com - May 4 at 8:07 AM
IDEXX Laboratories beats by $0.08, beats on revenueIDEXX Laboratories beats by $0.08, beats on revenue
seekingalpha.com - May 4 at 8:07 AM
IDEXX Laboratories Announces First Quarter ResultsIDEXX Laboratories Announces First Quarter Results
finance.yahoo.com - May 4 at 8:07 AM
IDEXX Labs Boosts 2018 EPS Outlook, But Backs Revenue View - Quick FactsIDEXX Labs Boosts 2018 EPS Outlook, But Backs Revenue View - Quick Facts
www.nasdaq.com - May 4 at 8:07 AM
IDEXX Labs Q1 top line up 16%; earnings up 30%; cash flow up 12%IDEXX Labs Q1 top line up 16%; earnings up 30%; cash flow up 12%
seekingalpha.com - May 4 at 8:07 AM
Idexx: 1Q Earnings SnapshotIdexx: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:07 AM
IDEXX Laboratories (IDXX) Beats on Q1 Revenues, View UpbeatIDEXX Laboratories (IDXX) Beats on Q1 Revenues, View Upbeat
finance.yahoo.com - May 4 at 8:07 AM
Idexx Laboratories (IDXX) Stock Rating Upgraded by ValuEngineIdexx Laboratories (IDXX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 4 at 12:41 AM
Zacks: Brokerages Expect Idexx Laboratories (IDXX) Will Post Quarterly Sales of $526.18 MillionZacks: Brokerages Expect Idexx Laboratories (IDXX) Will Post Quarterly Sales of $526.18 Million
www.americanbankingnews.com - May 3 at 4:26 AM
 Analysts Expect Idexx Laboratories (IDXX) to Announce $0.93 EPS Analysts Expect Idexx Laboratories (IDXX) to Announce $0.93 EPS
www.americanbankingnews.com - May 1 at 8:21 AM
Idexx Laboratories Reaches Analyst Target PriceIdexx Laboratories Reaches Analyst Target Price
www.nasdaq.com - April 29 at 8:10 AM
Idexx Laboratories (IDXX) Scheduled to Post Earnings on FridayIdexx Laboratories (IDXX) Scheduled to Post Earnings on Friday
www.americanbankingnews.com - April 27 at 1:16 AM
Idexx Laboratories (IDXX) Receives Average Recommendation of "Buy" from BrokeragesIdexx Laboratories (IDXX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 26 at 1:42 PM
Can CAG Growth for IDEXX (IDXX) Stock Return in Q1 Earnings?Can CAG Growth for IDEXX (IDXX) Stock Return in Q1 Earnings?
finance.yahoo.com - April 24 at 5:44 PM
Idexx Laboratories (IDXX) Lifted to "Buy" at Zacks Investment ResearchIdexx Laboratories (IDXX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 24 at 12:16 PM
Q1 2018 EPS Estimates for Idexx Laboratories Boosted by Analyst (IDXX)Q1 2018 EPS Estimates for Idexx Laboratories Boosted by Analyst (IDXX)
www.americanbankingnews.com - April 23 at 1:20 AM
 Analysts Anticipate IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $525.03 Million Analysts Anticipate IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $525.03 Million
www.americanbankingnews.com - April 16 at 4:00 AM
Reviewing IDEXX Laboratories (IDXX) & The CompetitionReviewing IDEXX Laboratories (IDXX) & The Competition
www.americanbankingnews.com - April 15 at 7:18 PM
IDEXX Laboratories (IDXX) versus The Competition Financial ReviewIDEXX Laboratories (IDXX) versus The Competition Financial Review
www.americanbankingnews.com - April 15 at 5:15 PM
IDEXX Laboratories (IDXX) Downgraded by BidaskClub to HoldIDEXX Laboratories (IDXX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - April 14 at 10:53 PM
$0.93 Earnings Per Share Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter$0.93 Earnings Per Share Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter
www.americanbankingnews.com - April 14 at 7:41 AM
Global Veterinary Molecular Diagnostics Market to Reach US$ 792.5 Mn by 2025, Says TMRGlobal Veterinary Molecular Diagnostics Market to Reach US$ 792.5 Mn by 2025, Says TMR
www.prnewswire.com - April 13 at 5:44 PM
IDEXX Laboratories (IDXX) & Its Peers Head-To-Head ContrastIDEXX Laboratories (IDXX) & Its Peers Head-To-Head Contrast
www.americanbankingnews.com - April 13 at 8:53 AM
IDEXX Laboratories to Release 2018 First Quarter Financial ResultsIDEXX Laboratories to Release 2018 First Quarter Financial Results
finance.yahoo.com - April 12 at 5:54 PM
Edited Transcript of IDXX presentation 6-Mar-17 3:25pm GMTEdited Transcript of IDXX presentation 6-Mar-17 3:25pm GMT
finance.yahoo.com - April 12 at 5:54 PM
Critical Comparison: IDEXX Laboratories (IDXX) & Its PeersCritical Comparison: IDEXX Laboratories (IDXX) & Its Peers
www.americanbankingnews.com - April 12 at 5:27 PM
Analyzing IDEXX Laboratories (IDXX) and BG Medicine (BGMD)Analyzing IDEXX Laboratories (IDXX) and BG Medicine (BGMD)
www.americanbankingnews.com - April 12 at 3:35 AM
IDEXX Laboratories (IDXX) Downgraded by Zacks Investment ResearchIDEXX Laboratories (IDXX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 9 at 1:55 PM
IDEXX Laboratories (IDXX) Receives "Buy" Rating from Stifel NicolausIDEXX Laboratories (IDXX) Receives "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 5 at 9:36 PM
Top Reasons Why I Like Abaxis In 2018Top Reasons Why I Like Abaxis In 2018
seekingalpha.com - April 4 at 4:25 PM

SEC Filings

Idexx Laboratories (NASDAQ:IDXX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Idexx Laboratories (NASDAQ:IDXX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Idexx Laboratories (NASDAQ IDXX) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.